Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an announcement.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its Emicizumab Injection (SYS6053), a biosimilar to Hemlibra for treating Hemophilia A. The modified bispecific humanized monoclonal antibody showed high similarity to the reference drug in quality, safety and efficacy in preclinical studies, positioning CSPC to enter China’s hemophilia biologics market and potentially broaden its hematology portfolio if clinical development succeeds.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company focused on developing and manufacturing innovative and generic drugs, including biologics. The group targets major therapeutic areas in China and globally, leveraging its research capabilities to expand its portfolio of advanced treatments across key disease segments.
Average Trading Volume: 122,539,802
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$110.2B
See more data about 1093 stock on TipRanks’ Stock Analysis page.